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Abstract
The underlying pathophysiology for bone growth defects in paediatric cancer patients receiving high dose methotrexate
chemotherapy remains unclear and currently there are no standardized preventative treatments for patients and survivors.
Using a model in young rats, we investigated damaging effects of long-term treatment with methotrexate on growth plate
and metaphyseal bone, and the potential protective effects of antidote folinic acid. This study demonstrated that chronic
folinic acid supplementation can prevent methotrexate-induced chondrocyte apoptosis and preserve chondrocyte
columnar arrangement and number in the growth plate. In the metaphysis, folinic acid supplementation can preserve
primary spongiosa heights and secondary spongiosa trabecular volume by preventing osteoblasts from undergoing
apoptosis and suppressing methotrexate-induced marrow adiposity and osteoclast formation. Systemically, plasma of
folinic acid supplemented rats, in comparison to plasma from rats treated with MTX alone, contained a significantly lower
level of IL-1b and suppressed osteoclast formation in vitro in normal bone marrow cells. The importance of IL-1b in
supporting plasma-induced osteoclast formation was confirmed as the presence of an anti-IL-1b neutralizing antibody
attenuated the ability of the plasma (from MTX-treated rats) in inducing osteoclast formation. Findings from this study
suggest that folinic acid supplementation during chronic methotrexate treatment can alleviate growth plate and
metaphyseal damages and therefore may be potentially useful in paediatric patients who are at risk of skeletal growth
suppression due to chronic methotrexate chemotherapy.
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Introduction
Bone growth involves the production of calcified cartilage in the
growth plate, which will be first converted into woven spongy bone
(composed of bony trabeculae of mineralized cartilage cores in the
primary spongiosa region) and then further modeled and
remodeled into lamellar trabecular bone (secondary spongiosa)
in the metaphysis [1]. These processes rely on the regulation of
growth plate chondrocyte proliferation, differentiation and apo-
ptosis, and differentiation and function of bone-forming cells
(osteoblasts) and bone resorptive cells (osteoclasts). Any disruption
to these carefully controlled cell processes (collectively termed
endochondral ossification) will result in bone growth defects. With
the development of more successful chemotherapy and improved
childhood cancer survivor rates, chemotherapy-associated bone
growth abnormalities in survivors of paediatric cancers, including
bone growth arrest, fractures, osteopenia and osteoporosis, have
become significant clinical problems [2,3,4,5]. Typically, bone
metabolism in children with acute lymphoblastic leukemia (ALL)
(the predominant childhood cancer) is known to be disturbed after
chemotherapy, resulting in reduced bone lengthening and bone
loss. Since bone growth defects or bone loss during childhood may
predispose to osteopenia and osteoporosis in later life, it is
important to understand the mechanisms of chemotherapy-
induced bone damage to the growing bones and develop strategies
for prevention of such damages.
Methotrexate (MTX) is prescribed widely for treatment of both
cancers (particularly for ALL and osteosarcoma) and rheumatoid
arthritis (RA). MTX acts by inhibiting the enzyme dihydrofolate
reductase, thus blocking thymidylate and purine synthesis [6].
While many studies have examined effects of long-term low-dose
MTX on bone metabolism and have reported no significant
adverse effects on bone mineral density (BMD) [7,8,9], long-term
intensive chemotherapy with MTX has been shown to cause
serious damage to bone development in paediatric patients
[10,11]. Despite some previous studies showing that MTX
chemotherapy can suppress skeletal growth by disrupting growth
plate structure and functioning of bone cells [12,13,14], how long-
term high-dose MTX chemotherapy (used typically in ALL
treatment) causes bone growth defects remains unclear. In
addition, due to high success rates and the intensified use of
chemotherapy in children (particularly with ALL that account for
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almost one third of childhood cancers and having a survival rate of
over 80%), it is important to develop potential strategies for
protecting bone growth during MTX chemotherapy. Folinic acid
(FA), an antidote that has been clinically used to reduce toxicity of
high dose MTX in soft tissues, has been recently shown to have
protective effects in the skeleton of young rats receiving acute
MTX chemotherapy [13]. However, no long-term studies have
examined potential protective effects of FA in chemotherapy-
induced bone damages. Using a chronic model in young rats
mimicking the MTX regimen in treating ALL, the current study
examined the structural, cellular and molecular damages to the
bone growth unit (growth plate and metaphysis) caused by long-
term high-dose MTX treatment, as well as the potential protective
effects of FA supplementary treatment.
Materials and Methods
Animal Trials and Specimen Collection
Groups of young male Sprague-Dawley rats of 5 weeks old were
randomly allocated into three treatment groups receiving saline,
MTX, or MTX plus FA (MTX+FA) (n = 6/group). MTX was
administered in two phases (Fig. 1) mimicking regimen for ALL
treatment [15]. During the induction phase, rats were sub-
cutaneously injected with MTX daily at 0.65 mg/kg for 5
consecutive days, followed by 9 days of rest. FA was injected
intraperitoneally 6 hours after MTX at 0.87 mg/kg. During the
maintenance phase (from day 15 or week 2 to week 6), rats
received MTX at 1.3 mg/kg twice weekly with or without FA at
1.3 mg/kg. By the end of week 6, rats were sacrificed humanely
using carbon dioxide overdose (Fig. 1). Ninety minutes prior to
sacrifice, rats were injected with 59-bromo-29-deoxyuridine (BrdU)
(Sigma, NSW, Australia) at 50 mg/kg to label S-phase nuclei for
studying cell proliferation. The above protocols were approved by
Women’s and Children’s Hospital Animal Ethics Committee
(South Australia).
Blood samples were collected for plasma used in analysis for its
ability in inducing osteoclast formation in vitro or in cytokine
ELISA assays. Left tibias were fixed in 10% formalin, decalcified
in Immuocal solution (Decal Corporation, Tallman, NY),
processed and embedded in paraffin for 4 mm thick sections for
histological analyses. Left femurs were stored at 280uC until used
for micro-computed tomography (m-CT) analysis. From the right
tibia, growth plate cartilage and metaphyseal bones were collected
for gene expression analysis.
Histological Analysis of Growth Plate and Metaphyseal
Bone Structure
Paraffin sections were dewaxed and stained with 0.3% Alcian
blue in 3% acetic acid followed by haematoxylin and eosin (H&E)
staining. In the growth plate, stained sections were used for
morphometric measurements of growth plate zonal heights and
columnar chondrocyte counts (cells/mm length). In the metaphy-
sis region, primary spongiosa heights, osteoblast and adipocyte
density measurements were made as described [8,14,16]. Briefly,
primary spongiosa heights were obtained by measuring the heights
between the end of growth plate and the top of secondary
spongiosa. Osteoblast density was obtained by counting cuboidal
mononuclear cells along the trabecular surface in 6 sequential
images along primary spongiosa as described [8,14], and expressed
as osteoblasts number per mm2 trabecular area. Adipocytes within
bone marrow area were counted in 4 random images within the
lower secondary spongiosa region, and expressed as adipocyte
number per mm2 marrow area. These measurements were made
on 3 separate sections of 200 mm interval.
Ex-vivo Micro-computed Tomography (m-CT) and
Analysis of Bone Parameters
Left femurs were used for examining treatment effects on
overall trabecular bone volume and trabecular bone structures by
a m-CT scanner (Skyscan 1076: Skyscan, Antwerp, Belgium),
with the scanner equipped at a 20–100 kV X-ray source and
a spot size of ,5 mm. Using the Skyscan software, a 1.0 mm
aluminium filter was selected for scanning rat bones. Other
settings were made in the scan dialog box with details of scan
width of 35 mm, resolution of 9 mm pixel, rotation step size 0.8
and averaging of 4 for noise reduction in order to achieve better
imaging. The following parameters were measured at a high
energy scan in the metaphysis: trabecular bone volume/total
volume ratio (BV/TV %), trabecular thickness (mm), number
(per mm) and separation (mm).
BrdU Labeling and in situ TUNEL Labeling of Growth
Plate Chondrocytes
To examine the treatment effects on growth plate chondrocyte
proliferation, BrdU labeling was performed as described [8,16].
BrdU+ cells were counted within the proliferative zone (cells/
mm2). To examine effects on chondrocyte apoptosis, terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)
(Roche Applied Science, NSW, Australia) was performed on
sections as instructed. Apoptotic cell density was expressed as
apoptotic cells/mm2 growth plate area (excluding cartilage/bone
transitional zone where the physiological apoptosis of hypertrophic
chondrocytes usually occurs).
In situ DNA Nick Translation for Labeling Apoptosis of
Osteoblasts
To examine treatment effects on the apoptosis of osteoblastic
cells, in situ nick translation (ISNT) reaction was conducted to label
the presence of fragmented DNA by direct incorporation of
labeled nucleotide in free 3’-OH termini using a nick translation
mixture (Roche, NSW, Australia). DNA strand breaks were then
detected by anti-Dig-peroxidase (Roche) and DAB reaction
(DAKO, CA). Osteoblast apoptosis was quantified within both
primary and secondary spongiosa along the surface of trabecular
bone, and expressed as apoptotic osteoblasts/mm2 trabecular
area.
Quantitative RT-PCR Analysis of Gene Expression
Real time RT-PCR was used to examine treatment effects on
mRNA expression of some major matrix proteins and regula-
tory genes, including growth plate cartilage protein collagen-II,
molecules involved in controlling apoptosis (Bcl-2, Bax, Fas, and
Fas-L), osteoblast differentiation (Osterix, Osteocalcin), osteoclast
Figure 1. Dosing schedules for 6 weeks with the induction and
maintenance phases of MTX chemotherapy. *indicates one
injection of MTX with or without folinic acid (FA).
doi:10.1371/journal.pone.0046915.g001
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differentiation (RANKL, OPG, TNF-a) and adipogenesis
(PPARc). Briefly, total RNA from the growth plate and
metaphysis was extracted with TRI reagent (Sigma) then DNase
treated with TURBO DNA-freeTM Kit (Ambion, Austin, TX) for
the removal of any contaminating DNA. Samples with an
A260/A280 ratio of 1.8 or above were used to synthesize single
stranded cDNA using High Capacity RNA-to-cDNA Kit
(Applied Biosystems, Sydney, Australia). SYBR Green PCR
assays (Applied Biosystems) for each target molecule and
reference gene Cyclophilin A (Cyc-A) were performed using
primers (Table 1) [16,17,18] in triplicate on cDNA samples.
PCR assays were run on a 7500 Fast Real-Time PCR System
(Applied Biosystems). Analysis of gene expression was done
using the comparative Ct (22DCT ) method [17].
Measurement of RANKL and Pro-inflammatory Cytokines
in Plasma
Enzyme-linked immunosorbent assay (ELISA) was performed to
measure osteoclastogenic cytokines in plasma of treated vs. control
rats using ELISA kits for TNF-a (BD Biosciences, San Diego, CA),
RANKL (R&D Systems, Minneapolis, MN) and IL-1b (R&D
Systems).
In vitro Osteoclast Formation Induced by Plasma from
Treated Rats
To determine whether circulating factors may play a role in
osteoclastogenesis after long-term MTX treatments, in vitro
osteoclast formation assay was performed to examine whether
plasma derived from treated rats could induce osteoclast formation
from bone marrow cells of normal rats. Briefly, non-adherent
hematopoietic cells isolated from normal rats were plated in 96-
well trays at the density of 36105 cells/well in triplicate, and
cultured overnight in a-MEM media containing 50 mg/ml Pen/
Strep, 15 mM HEPES, 10 ng/ml macrophage-colony stimulating
factor (M-CSF) (Peprotech, Rocky Hill, NJ), and 10% plasma from
control rats or treated rats. Cells were then fed the next day with
similar plasma-containing media excluding M-CSF and any other
exogenous osteoclastogenic factors except RANKL for the positive
control (M-CSF+RANKL). To determine whether IL-1b plays
a role in plasma-induced osteoclast formation, a neutralizing
antibody against IL-1b (R&D Systems) at two different concentra-
tions (0.04 and 0.08 ng/ml) was added to the plasma-containing
media as described [19]. A normal goat IgG control IgG was also
used at the same concentrations as the neutralizing IL-1b
antibody. In addition, a positive control was included alongside
for comparison with the osteoclast formation induced by 10 ng/ml
M-CSF and 30 ng/ml RANKL (Peprotech) in the absence of any
additional rat plasma as described [8]. Cell culture ended at day 5,
and cells were fixed in 4% formaldehyde and TRAP-stained for
osteoclasts [8]. To aid identifying osteoclasts, cells were counter-
stained with Hoechst 33258 fluorescent dye (Invitrogen) for
visualization of nuclei. TRAP+ cells containing three or more
nuclei were identified as osteoclasts. Results were expressed as
percentage of osteoclast formation induced by the positive control
(M-CSF+RANKL treated culture) as described [19].
Statistics
Data are presented as means 6 SEM and analysed by one-way
analysis of variance (ANOVA) with GraphPad Prism 6 Software.
When the significance levels (P,0.05) were achieved, a post hoc
analysis of groups was performed using a Tukey’s test. Significant
values are indicated as follows: * = P,0.05, ** = P,0.01,
*** = P,0.001. All measurements were done with n= 6 rats per
treatment group.
Results
Treatment Effects on Growth Plate Structural Changes
and Chondrocyte Proliferation
Overall, chronic treatment with MTX alone or together with
supplementary FA caused no obvious structural changes to the
growth plate (Fig. 2A–2C). Histomorphometric measurements
also revealed no differences in both zonal and total growth plate
thicknesses between all treatment groups (Fig. 2D–2F). However,
counting of cells per chondrocyte column revealed a significant
reduction of chondrocyte numbers after long-term MTX treat-
ment compared to control rats (P,0.01), while supplementary
treatment with FA partially preserved the chondrocyte numbers
(P,0.05 vs. MTX) (Fig. 2H). Apart from the significant
reduction in chondrocyte numbers observed, chondrocytes in
MTX-treated rats appeared to have disrupted columnar arrange-
ment when compared to control or FA-supplemented rats.
However, BrdU labeling for chondrocyte proliferation revealed
no differences in density of BrdU+ cells between all treatment
groups (Fig. 2G and 2I). In addition, RT-PCR analysis revealed
no significant changes in mRNA expression of the major cartilage
protein collagen-II (data not shown).
Table 1. Primer sequences used in this study.
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Treatment Effects on Chondrocyte Apoptosis and
Expression of Apoptosis-regulatory Genes
Apoptotic cells chondrocytes are normally found at the growth
plate-bone transitional region, but rarely identified within the
growth plate proliferative and hypertrophic zones (Fig. 3A). After
6 weeks of high-dose MTX treatment, a significant induction of
chondrocyte apoptosis was observed within the growth plate in
both the proliferative and hypertrophic zones as shown by
fluorescent TUNEL positive staining and density quantification
(cells/mm2) (P,0.001 vs. controls) (Fig. 3B & 3D). On the other
hand, FA supplementation significantly suppressed MTX-induced
chondrocyte apoptosis (P,0.001) (Fig. 3C & 3D).
Quantitative RT-PCR analysis was used to examine expression
of apoptosis regulatory genes involved in both mitochondrial
pathway (Bcl-2 and Bax) and death receptor pathway (Fas and
Fas-L) [20,21]. While levels of expression of both anti-apoptosis
gene Bcl-2 and pro-apoptosis gene Bax were not affected by
treatments (data not shown), expression of both death receptor Fas
and its ligand (Fas-L) showed a trend of up-regulation in MTX-
treated rats, which was not seen in rats receiving supplementary
Figure 2. Effects of treatments with MTX alone or with supplementary folinic acid (FA) for 6 weeks on overall structures of rat tibia.
H&E staining of rat tibia from control (A), MTX-treated (B) and MTX+FA treated rats (C) at week 6. GP= growth plate, PS =primary spongiosa,
SS = secondary spongiosa. H&E staining of growth plates from week 6 control (D), MTX-treated (E) and MTX+FA (F) treated rats. R = resting zone,
P = proliferative zone and H=hypertrophic zone. (G) BrdU labeling (arrows) of chondrocytes at proliferative zone of growth plate. (H) Treatment
effects on columnar chondrocyte number, which were measured along the red dotted line. (I) Treatment effects on growth plate chondrocyte
proliferation. Scale bars on panels A–C=500mm, D–F= 250 mm and G= 150 mm.
doi:10.1371/journal.pone.0046915.g002
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FA treatment (Fig. 3E & 3F). These results suggest that the death
receptor pathway may possibly contribute towards MTX-induced
chondrocyte apoptosis, which may be prevented by FA supple-
mentation.
Treatment Effects on Structural Changes in Metaphysis
Metaphysis is made up with primary and secondary spongiosa,
where the primary spongiosa consists of the mineralized cartilage
derived from the growth plate, while secondary spongiosa is
composed of enlarged mineralized bony trabeculae modeled or
remodeled from the primary spongiosa. Histomorphometric
analysis of the metaphyseal bone revealed a significant reduction
in primary spongiosa heights after 6 week of high-dose MTX
treatment (P,0.05 vs. controls), while FA supplementation was
able to prevent this reduction (Fig. 4A–4D) (P,0.05 vs. MTX).
Further examination of structural changes in metaphysis with m-
CT revealed that the MTX treatment caused an insignificant
reduction in trabecular bone volume (BV/TV%) when compared
to control rats (20.1764.2 vs. 24.9262.1%), and that FA
supplementation was able to prevent this bone loss (27.6564.1
for MTX+FA vs. 20.1764.2% for MTX alone) (Fig. 4E–4H). In
addition, when compared to control rats, long-term high-dose
MTX treatment caused a non-significant reduction in trabecular
number (2.49 vs. control 3.15/mm), a slight increase of trabecular
thickness (0.081 vs. 0.071 mm) and trabecular separation (0.26 vs.
0.25 mm) (Fig. 4H). When compared to MTX alone group, FA
supplementation resulted in a greater number of trabeculae (3.73
vs. 2.49/mm) and a reduction of trabecular spacing (0.20 vs.
0.26 mm) (Fig. 4H). Consistent with these m-CT findings,
quantitative histomorphometric analysis on H&E stained bone
sections obtained similar results on trabecular bone volume and
trabecular structure, with more obvious changes observed in
secondary spongiosa (data not shown).
Treatment Effects on Osteoblast Density and Osteoblast
Apoptosis
Trabecular bone volume and structure are directly influenced
by numbers and activity of osteoblasts. Counting of osteoblasts on
H&E stained sections revealed that high-dose MTX treatment
significantly reduced osteoblast density in the primary spongiosa
but not in the secondary spongiosa when compared to control rats
(P,0.01), while FA supplementation significantly preserved the
osteoblast density (P,0.01 vs. MTX) (Fig. 5A–5D). To de-
termine mechanisms for treatment-induced changes in osteoblast
density, treatment effects on osteoblast proliferation and apoptosis
were assessed. While BrdU labeling revealed no obvious changes
in osteoblast proliferation (data not shown), apoptosis analysis by
in situ Nick Translation labeling revealed that long-term high-dose
MTX treatment caused a trend of more apoptosis among
osteoblasts in metaphysis (Fig. 5E, 5F & 5H). Interestingly, FA
supplementary treatment appeared to prevent the MTX-induced
osteoblast apoptosis in both primary and secondary spongiosa
(Fig. 5G & 5H).
Treatment Effects on Osteoclast Density and Expression
of Genes Regulating Osteoclastogenesis
Counting of TRAP+ osteoclasts adhering on trabecular surface
revealed that MTX treatment significantly increased osteoclast
Figure 3. Effects of treatments with MTX alone or with supplementary folinic acid (FA) for 6 weeks on growth plate chondrocyte
apoptosis. In Situ TUNEL labeling of growth plate apoptotic chondrocytes from week 6 control (A), MTX-treated (B), and MTX+FA (C) treated rats,
with arrows pointing to TUNEL positive apoptotic chondrocytes, characterized by fragmented nuclei (enlarged version shown in dotted square). (D)
Treatment effects on density of apoptotic chondrocytes in growth plate. (E, F) Treatment effects on mRNA expression of apoptotic death receptor
pathway genes Fas and Fas-L relative to Cyclophilin-A. Scale bar on panels A–C=200 mm.
doi:10.1371/journal.pone.0046915.g003
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density in the primary spongiosa (P,0.01 vs. controls), while
supplementary FA treatment significantly suppressed this increase
(P,0.05 vs. MTX) (Fig. 6A –6D). As a mean to examine
expression of key genes promoting osteoclastogenesis locally in
bone, RT-PCR analysis revealed no significant changes in
RANKL/OPG mRNA expression ratio (Fig. 6E) and levels of
pro-inflammatory cytokines including TNF-a, IL-1b and IL-6 in
the metaphysis (data not shown).
Figure 4. Effects of treatments with MTX alone or with supplementary folinic acid (FA) for 6 weeks on metaphysis structure. H&E
alcian staining of metaphyseal bone in control (A), MTX-treated (B) and MTX+FA (C) treated rats, with dotted lines marking the primary spongiosa
zone. (D) Treatment effects on primary spongiosa height. m-CT longitudinal cross-sections of femur from a control (E), MTX-treated (F), and MTX+FA
(G) treated rat, with area traced in red dotted lines being used for measurement of trabecular bone volume and structures. (H) Treatment effects on
trabecular bone volume and structural changes. BV/TV= Bone volume/Tissue volume, Tb = Trabecular. Scale bar on panels A–C= 250 mm.
doi:10.1371/journal.pone.0046915.g004
Figure 5. Effects of treatments with MTX alone or with supplementary folinic acid (FA) for 6 weeks on osteoblast density and
apoptosis. H&E-stained sections of a tibia from a control (A), MTX-treated (B) and a MTX+FA (C) treated rat, with arrows pointing to osteoblasts. (D)
Treatment effects on osteoblast density in primary spongiosa. In Situ Nick Translation labeling detecting apoptotic osteoblasts (pointed by arrows) in
metaphysis bone from a control (E), MTX-treated (F), and a MTX+FA (G) treated rat. (H) Treatment effects on osteoblast apoptosis in metaphysis bone.
Scale bars on panels A–C=100 mm and E–G= 125 mm.
doi:10.1371/journal.pone.0046915.g005
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Potential systemic effects of treatment were investigated by
examining ability of the plasma alone from treated and control rats
(without exogenous M-CSF and RANKL added) in promoting
osteoclast formation from normal bone marrow cells. In vitro
osteoclast formation assays revealed that plasma obtained from
MTX-treated rats was able to induce more osteoclast formation
when compared to plasma from control rats and positive control
with exogenous M-CSF and RANKL, despite statistically in-
significant. However, plasma obtained from MTX+FA treated rats
induced significantly fewer osteoclasts compared to plasma from
MTX-treated rats (P,0.05) (Fig. 7A–7E). To identify potential
circulating osteoclastogenic factors, ELISA assays revealed no
obvious differences in TNF-a and RANKL concentrations in
plasma obtained from both treated and control rats (data not
shown). However, IL-1b concentration in the plasma was
significantly increased following 6-week MTX administration
(P,0.01 vs. controls) (Fig. 7F), and FA supplementary treatment
was found to partially suppress MTX-induced increase in IL-1b
level (Fig. 7F). To investigate a role of IL-1b in plasma-induced
osteoclast formation in vitro, the osteoclastogenesis assay was also
performed in the presence of a neutralizing antibody against IL-1b
as well as a control antibody. Despite statistically being in-
significant, the ability of enhancing osteoclast formation by plasma
from MTX-treated rats was found to be reduced in the presence of
the anti-IL1-b neutralizing antibody in a dose-dependent manner,
while the control IgG at both doses did not reduce osteoclast
formation induced by plasma from MTX-treated rats, demon-
strating specificity of the effects of the anti-IL1-b neutralizing
antibody observed (Fig. 7G). Taken together, these data suggest
that MTX chemotherapy-induced increase in plasma IL-1b may
play a role in inducing osteoclast formation systemically.
Treatment Effects on Bone Marrow Adipocyte Density
To investigate whether long-term MTX treatment is associated
with an increase in marrow adiposity, density of adipocytes was
quantified within the bone marrow at the lower secondary
spongiosa region on H&E stained tibia sections. This analysis
revealed that MTX treatment caused a significant increase in
adipocyte density within the bone marrow when compared to the
normal control (P,0.001) (Fig. 8A, 8B & 8D). However, FA
supplementation was able to significantly suppress this adiposity
phenotype (P,0.001) (Fig. 8B, 8C & 8D). RT-PCR analysis
revealed insignificant increased mRNA expression of adipogenic
transcription factor PPARc after MTX treatment which appeared
to be suppressed by MTX+FA treatment (Fig. 8E).
Discussion
Due to the high success rate and intensifying use of chemo-
therapy in paediatric cancers, chemotherapy-induced bone growth
defects, osteoporosis, osteonecrosis, and fractures are becoming
major long-term adverse effects in young cancer patients and
survivors. Despite many clinical and some animal studies
[12,14,16] that have reported bone damage during and after
chemotherapy, there is a lack of adjuvant treatments for protecting
bone growth during childhood cancer chemotherapy. Using
Figure 6. Effects of treatments with MTX alone or with supplementary folinic acid (FA) for 6 weeks on osteoclasts. TRAP-stained
sections of tibia from a control (A), MTX-treated (B), and a MTX+FA treated rat (C), with arrows pointing to multinucleated TRAP+ osteoclasts. (D)
Treatment effects on osteoclast density in primary spongiosa. (E) Treatment effects on metaphyseal bone RANKL/OPG mRNA expression ratio as
determined by real time RT-PCR analysis. Scale bar on panels A–C= 200 mm.
doi:10.1371/journal.pone.0046915.g006
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a chronic rat model of chemotherapy mimicking the clinical
protocol with the commonly used anti-metabolite methotrexate
(MTX), the current study observed that long-term high dose MTX
chemotherapy reduces endochondral bone formation and in-
creases bone resorption and marrow fat content, and that FA
supplementation can prevent these adverse effects.
Effects of Chronic Methotrexate Treatment on Growth
Plate
Growth plate chondrocyte numbers and rates of their pro-
liferation and apoptosis directly correlate to the longitudinal
growth rate [22]. In the current study, long-term MTX
chemotherapy caused a significant loss of growth plate chondro-
cytes and their columnar arrangement. To examine mechanisms
of chondrocyte loss, the current study revealed that long-term
high-dose MTX treatment caused no significant changes in
chondrocyte proliferation. This is in contrast to previous studies
that reported decreased growth plate cell proliferation in rats
treated with high-dose MTX for a short-term (5 daily injections at
0.75 mg/kg) [13,14]. However, consistent to the current study,
a few studies have reported that MTX alone had no effects on
proliferative response of chondrocytes both in vivo and in vitro
Figure 7. Osteoclast formation in vitro as induced by plasma from rats treated with MTX alone or with supplementary folinic acid
(FA) for 6 weeks. In vitro osteoclast formation from normal rat bone marrow cells as induced by M-SCF+RANKL (A), or by plasma alone obtained
from rats treated for 6 weeks with saline control (B), MTX (C), or MTX+FA combination (D), with arrows pointing to multinucleated TRAP+ osteoclasts
formed. Hoechst stain was performed to aid visualising nuclei of TRAP+ cells (in square). (E) Comparison of osteoclast formation as induced by plasma
from rats of different treatment groups, with results expressed as percentage of osteoclasts induced by M-CSF+RANKL (positive control). (F) Plasma
concentrations of IL-1b at week 6. (G) Effects of the presence of a IL-1b neutralizing antibody or control IgG at different concentrations on plasma-
induced osteoclast formation with plasma from control or MTX-treated rats, with results expressed as percentage of osteoclasts induced by M-
CSF+RANKL. Scale bar on panels A–D= 100 mm.
doi:10.1371/journal.pone.0046915.g007
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[12,23]. Similarly, while a previous study has demonstrated that 5
consecutive doses of MTX reduced collagen-II mRNA expression
in growth plate of treated rats, the current study revealed that
collagen-II expression in the growth plate was not significantly
suppressed in rats receiving long-term MTX chemotherapy. These
studies suggest that chondrocyte proliferation and collagen-2
expression appear to be more severely affected after acute
consecutive daily MTX treatment in comparison to chronic twice
weekly treatment, which may be due to differences in the
cumulative drug effects with time.
Apart from appropriate chondrocyte proliferation, production
of calcified cartilage scaffold for trabecular bone deposition also
relies on appropriate balance of survival vs. apoptosis of
chondrocytes. The current study revealed that chronic high-dose
MTX treatment has a profound effect in inducing chondrocyte
apoptosis at the lower proliferative and upper hypertrophic zones,
where apoptosis is normally not observed, which is consistent with
previous animal studies [14,16]. Two major pathways are known
to be involved in chemotherapy-induced apoptosis, including the
death receptor pathway and mitochondrial dysfunction pathway
[24]. The current study revealed consistent findings to one
previous acute study, that long-term high-dose MTX treatment
caused a notable induction of Fas and Fas-L expression [14].
Interestingly, high-dose corticosteroid treatment in rats was
reported to promote apoptosis of chondrocytes and osteocytes
via suppression of Bcl-2 and induction of Bax expression [25],
suggesting different chemotherapeutic agents may induce apopto-
sis by different apoptotic pathways.
Effects of Chronic Methotrexate Treatment on
Metaphyseal Bone and Fat Contents
Mirroring the growth plate damages by chronic MTX
chemotherapy, the current study further revealed a reduction in
the thickness of primary spongiosa and reduced metaphyseal bone
volume after chronic MTX treatment. m-CT analysis also revealed
that following the MTX treatment, bony trabeculae were fewer in
number and more separated in spacing, a finding which is
consistent with that reported in a short-term rat study [14].
The numbers and activities of osteoblasts and osteoclasts on the
trabecular bone surface determine and modify the number, size
and shape of bone trabeculae, influencing bone mass. In rats,
short-term MTX administration was able to reduce osteoblast
density by suppressing osteoblast and preosteoblast proliferation
in vivo [14]. The current study revealed that chronic high-dose
MTX treatment was able to decrease osteoblast density, which was
found associated with the induction of osteoblast apoptosis rather
than reduction in proliferation. However, quantitative RT-PCR
analysis revealed a trend of increase in gene expression of
osteogenic transcription factor osterix and major osteoblast protein
osteocalcin in metaphyseal bone, suggesting a trend of increase in
osteoblast maturation and probably representing a repair response
for osteogenic potential following chronic high-dose MTX-
treatment. Consistently, in a recent study, while there was
a reduction in osteoblast density in rats treated chronically with
low-dose MTX, the size of osteoprogenitor pool within bone
marrow of the treated rats was increased [8]. This again suggested
a trend of greater osteoblast differentiation potential within the
bone marrow after long-term MTX chemotherapy. Interestingly,
Figure 8. Effects of treatment with MTX alone or with supplementary folinic acid (FA) for 6 weeks on adipocyte density and mRNA
expression of PPARc. H&E-stained sections of tibia from a control (A), MTX-treated (B) and MTX+FA treated rat (C). Treatment effects on adipocyte
density within bone marrow area of secondary spongiosa (D), and mRNA expression of PPARg relative to Cyclophilin-A (E). Scale bar on panel
C = 250 mm, which applies to A and B.
doi:10.1371/journal.pone.0046915.g008
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the increase in osteogenic potential during maintenance MTX
chemotherapy (of a lower intensity) is in contrast with the
decreased osteogenic potential of bone marrow stromal progenitor
cells after 5 consecutive high-dose MTX treatment (representing
the intensive induction phase) [26]. It is possible that the increased
osteogenic potential after the long-term maintenance MTX
treatment represents a recovery mechanism compensating for
the damaged bone environment caused during the intense
induction treatment phase.
Previous clinical studies have reported a low bone mass and an
excess bone marrow content (adiposity) following the treatment of
childhood ALL [27,28]. Similarly, the phenomenon for reduced
bone volume with increased marrow adiposity is also well
described in ageing-related osteoporosis [29]. In the current study,
accompanying the bone volume being reduced following long-
term high-dose MTX administration, adipocyte density was found
significantly increased within the metaphysis of treated rats,
despite the increase in expression of adipogenic transcription
factor PPARc [30] not being statistically significant in the
metaphysis. Previously, PPARc has been identified to be a key
transcriptional factor for adipocyte differentiation that regulates
the lineage commitment of both marrow MSCs towards
adipocytes and away from osteoblasts [31]. A recent study has
demonstrated that acute intensive MTX treatment (equivalent to
the induction phase of the current study) caused a significant
switch of bone marrow stromal progenitor cells from osteogenesis
to adipogenesis [26], with osteogenic transcription factors Runx2
and Osterix being decreased but adipogenic genes PPARc and
FABP4 being up-regulated in the stromal cell population. In the
current study, the increased adipocyte density and reduced
osteoblast density with unchanged expression of adipogenic and
osteogenic regulatory genes could be related to the possibility of
increased adipogenesis at the expense of osteoblastogenesis within
the bone marrow occurring during the early intensive induction
phase of MTX treatment as observed [26], but not during the
maintenance phase. Mechanisms underlying MTX-induced po-
tential bone/fat switch remain to be investigated.
Effects on Metaphyseal Bone Resorption and Circulating
Cytokines
Since the imbalance of bone formation and bone resorption
processes causes skeletal morbidity, the current study also
examined the treatment effects on bone resorptive osteoclasts
and revealed that long-term MTX chemotherapy significantly
increased osteoclast density on trabecular bone surface (2 folds of
control). A recent ex vivo study using bone marrow cells obtained
from rats treated with MTX for 5 days revealed an increase in
osteoclast precursor (OCP) cell pool expressing preosteoclast
surface marker CD11b+ [8], which is consistent with the
observed increased osteoclast density on bone surface of treated
rats [8]. Clinically, long-term glucocorticoid treatment is known
to increase production of the major osteoclastogenic factor
RANKL by osteoblasts, resulting in more osteoclast formation
and bone resorption with a net loss of bone over time [32]. In
the current study, however, gene expression analysis revealed
a lack of significant changes in expression of RANKL/OPG ratio
and in levels of osteoclastogenic cytokines (IL-6, TNF-a and IL-
1b) in the metaphysis, indicating that expression of osteoclasto-
genic signals was not affected locally in bone during maintenance
phase of MTX chemotherapy. This observation perhaps
indicates that bone loss was mainly resulting from the more
severe cellular and molecular damages during the intensive
induction chemotherapy phase [14,33,34], in which the struc-
tural damages resulting from the initial intensive induction
treatment may have persisted into the maintenance phase, where
molecular recovery starts to take place in order to compensate
for the damaged bone environment.
While levels of expression of osteoclastogenic signals were not
affected locally in the metaphysis, blood plasma obtained from
MTX-treated rats was shown able to induce more osteoclast
formation in vitro in bone marrow cells from normal rats. Despite
the results were not statistically significant, plasma from MTX-
treated animals was able to induce more osteoclast formation than
the positive control supported by exogenous osteoclastogenic
growth factors (MCSF+RANKL), suggesting the systemic contri-
bution of MTX chemotherapy to bone resorption. However, the
extent of plasma contribution to osteoclast formation was found
not as substantial as that observed in the acute model [19],
suggesting that while the plasma systemic contribution to bone loss
still remains during maintenance chemotherapy, the contribution
and damages are greater during the intensive induction chemo-
therapy phase. In addition, the variation between plasma of
MTX-treated animals in inducing osteoclast formation may also
contribute to the lack of significant effects seen, a limitation that
could be avoided by increasing the number of rat plasma per
group in future studies.
Interestingly, protein levels of IL-1b were shown significantly
elevated when compared to normal rat plasma. Furthermore,
despite the statistical insignificance, the blunting effect of IL-1b
neutralizing antibody in the plasma-induced osteoclast formation
was observed in a dose-dependent manner, which suggests the
importance of IL-1b in promoting osteoclast formation. However,
the significant increase in IL-1b concentration within the plasma
from MTX-treated rats did not closely reflect the extent of plasma-
induced osteoclast formation, suggesting that the systemic IL-1b
may only partially contribute to plasma-induced osteoclast
formation. It is known that IL-1b promotes bone resorption and
mediates bone resorption in inflammatory bone loss disorders. It
participates in various stages of osteoclast development both in vivo
and in vitro, including fusion of mononuclear pre-osteoclasts,
potentiating osteoclast function and prolonging survival of
osteoclasts [35,36,37]. IL-1b is secreted by osteoclast precursor
(OCP) cells, but unlike TNF-a and RANKL, IL-1b cannot induce
osteoclast formation directly from OCPs in vitro [38]. In addition to
the known effect that IL-1b can induce osteoclast formation
indirectly through up-regulation of RANKL via osteoblast/
stromal cells [39], one recent study demonstrated that IL-1 can
stimulate osteoclast formation directly from OCPs when they
overexpress c-Fos, without addition of other cytokines [40].
Incidentally, MTX has previously been shown to increase the
number of CD11b+ OCPs, which may provide an explanation of
increased IL-1b as it is secreted by OCPs. In the study, without the
up-regulation of RANKL protein within the systemic circulation
after MTX treatment, plasma IL-1b appears to play a role in
inducing more osteoclast formation. It could be possible that the
MTX-induced increased OCPs may express a high level of c-Fos,
therefore an increased level of systemic IL-1b could potentially
induce osteoclast formation directly to mediate bone loss.
However, further investigations are required to confirm this.
Moreover, the unchanged RANKL protein levels in the plasma of
MTX-treated rats do not mean RANKL is not required for
osteoclast formation. RANKL is critical for osteoclastogenesis, and
this study revealed that in the presence of RANKL (even without
the upregulation of its expression), IL-1b upregulation within the
circulation was able to induce more osteoclast formation.
However, the possibility of other systemic factors contributing to
bone loss cannot be ruled out.
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Prevention of Methotrexate-induced Bone Damage by
Folinic Acid Supplementation and Clinical Relevance
Due to the high success rates in cancer treatment, MTX
remains to be an important component of paediatric chemother-
apy. MTX chemotherapy is associated clinically with bone pain,
bone loss and increased fracture risks [41], and chronic use of
MTX alone or in combination with other chemotherapy agents
may lead to failure of BMD recovery even after discontinuation of
treatment [42]. Therefore, it is necessary to develop potential
strategies to protect bone growth during chemotherapy. Since
folate is essential for cell proliferation and survival [43,44], folate
deficiency caused by repeated use of MTX could be one of the
possible causes of skeletal defects. Folinic acid (FA) is an antidote
that has been clinically used for supplementing MTX therapy to
reduce hepatotoxicity and gastrointestinal side effects without
lowering the efficacy of MTX [45]. Recently, FA treatment was
found to protect against MTX-induced bone damage in short-
term animal study [13]. The current study further revealed that
FA supplementary treatment can diminish the damaging effects of
chronic high-dose MTX at growth plate by preventing MTX-
induced chondrocyte apoptosis via the suppression of pro-
apoptotic molecules involved in the death receptor pathway.
Thus FA supplementation preserved chondrocyte number and
their columnar arrangement in MTX-treated rats. At the
metaphysis, FA supplementation was able to preserve primary
spongiosa heights and overall trabecular bone volume in MTX-
treated rats; and this bone-protective effect was probably related to
FA function in preventing osteoblast apoptosis (thus preserving
osteoblast density) and preventing a higher density of osteoclasts
(reducing bone resorption). Consistently, FA supplementation was
previously shown to preserve osteoblast numbers and bone
marrow stromal cell pool in rats receiving acute intensive MTX
chemotherapy [13] and to suppress MTX-induced increased
osteoclast density in rats treated with MTX at a high dose for
a short term or at a low dose for a long-term [8]. While the current
study revealed no significant changes in expression of genes
involved in osteoclastogenesis in metaphyseal bone, FA supple-
mentation was found to suppress the ability of plasma obtained
from MTX-treated rats in supporting in vitro osteoclast formation.
Interestingly, FA supplementation in blocking the ability of plasma
from MTX-treated rats in inducing osteoclast formation was
found associated with only partial abrogation of induction of IL-1b
levels in the circulation, and the greater extent of reduction of
osteoclast formation was not reflected by the insignificant lower
level of IL-1b from the plasma of FA-supplemented rats. It is
possible that while IL-1b may have contributed to osteoclastogen-
esis after MTX chemotherapy, effects of MTX+FA supplementary
treatment on suppressing IL-1b and thus its likely role to the FA
treatment-induced overall reduced osteoclast formation have been
minimal. It is likely that FA may suppress MTX-induced
osteoclastogenesis through other factors/cytokines (in addition to
IL-1b) which will need to be addressed in future studies. In
addition, FA may also act through other systemic mechanisms to
suppress osteoclast formation. Clinical studies showed that FA
administration thrice weekly can suppress serum malondialdehyde
(S-MDA, a marker of oxidative stress and lipid peroxidation) [46],
and oxidative stress is known to be associated with osteoporosis
and other bone pathology. However, the mechanisms for systemic
rescuing effect of FA in MTX chemotherapy require further
investigation. Moreover, the current study revealed that FA
supplementation can significantly reduce bone marrow adiposity
resulted from MTX chemotherapy, indicating it may potentially
preserve bone volume by preserving osteogenesis and suppressing
osteoclastogenesis and adipogenesis. Present study lays the ground
work for future investigation on whether FA prevents skeletal
complications in childhood survivors and further scope to optimize
the potential dual action of FA to reduce of chemotherapy induced
soft tissue toxicity and skeletal complications.
Conclusions
Using a chronic model in young rats mimicking the commonly
used clinical protocol, the current study has identified that chronic
high dose MTX chemotherapy causes bone growth defects by
reducing endochondral bone formation and increasing bone
resorption and marrow adiposity, and that folinic acid supple-
mentation can prevent these adverse effects. While folinic acid
treatment has been used in childhood chemotherapy to reduce
toxicities of high dose MTX in soft tissues, our study suggests that
folinic acid may be potentially useful in paediatric patients who are
at risk of skeletal growth suppression and bone loss as a result of
chronic high-dose MTX chemotherapy.
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